Indaptus raises $6M via convertible preferred; Lazar appointed Chairman and Co-CEO

Indaptus Therapeutics, Inc.

David Lazar invests $6M for 300K Series AA and 700K Series AAA shares convertible into 111M common shares after stockholder approval.
Lazar appointed Chairman and Co-CEO; board adds Avraham Ben-Tzvi; directors Martell and Karah resign.
Special meeting by Mar 31, 2026 to approve conversion, authorized share increase, written consent, reverse split, and Lazar board nominees.
Executive officers modify employment: reduce notice to 10 days, waive severance for stock/cash; CMO Waltzman resigns with $207K bonus.
Issuance under Regulation S exemption; proceeds for operations, severance, working capital.

item 1.01 item 3.02 item 3.03 item 5.03 item 5.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Indaptus Therapeutics, Inc. issued 300,000 shares of Series AA Convertible Preferred Stock and 700,000 shares of Series AAA Convertible Preferred Stock of preferred stock to David E. Lazar for $6.00 per share of Preferred Stock for aggregate gross proceeds of $6.0 million.

Security: preferred stock
Shares: 300,000 shares of Series AA Convertible Preferred Stock and 700,000 shares of Series AAA Convertible Preferred Stock
Purchaser: David E. Lazar
Consideration: $6.00 per share of Preferred Stock for aggregate gross proceeds of $6.0 million

Exact text from the filing

on December 22, 2025, Indaptus, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with David E. Lazar, pursuant to which he agreed to purchase from the Company 300,000 shares of Series AA Convertible Preferred Stock (the “Series AA Preferred Stock”) and 700,000 shares of Series AAA Convertible Preferred Stock (the “Series AAA Preferred Stock” and, together with the Series AA Preferred Stock, the “Preferred Stock”) of the Company at a purchase price of $6.00 per share of Preferred Stock for aggregate gross proceeds of $6.0 million

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Indaptus Therapeutics, Inc. entered into Purchase Agreement with David E. Lazar valued at $6.0 million (effective 2025-12-22).

Action: entry
Agreement: equity purchase
Counterparty: David E. Lazar
Value: $6.0 million
Effective: 2025-12-22

Exact text from the filing

On December 22, 2025, Indaptus, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with David E. Lazar, pursuant to which he agreed to purchase from the Company 300,000 shares of Series AA Convertible Preferred Stock (the “Series AA Preferred Stock”) and 700,000 shares of Series AAA Convertible Preferred Stock (the “Series AAA Preferred Stock” and, together with the Series AA Preferred Stock, the “Preferred Stock”) of the Company at a purchase price of $6.00 per share of Preferred Stock for aggregate gross proceeds of $6.0 million

View on SEC.gov

Browse all equity issuances →

Indaptus Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-029107

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.